Collectively, these data demonstrate that, in SCLC cell lines, SLFN11 expression determines cellular sensitivity to both talazoparib and the talazoparib-temozolomide combination, suggesting the potential value of combining temozolomide with talazoparib in SLFN11-positive SCLC. Here, SLFN11 is linked to small cell lung carcinoma.